Journal Mobile Options
Table of Contents
Vol. 47, Suppl. 2, 2001
Issue release date: 2001

Antiproliferative Effect of Somatostatin and Analogs

Bousquet C. · Puente E. · Buscail L. · Vaysse N. · Susini C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Over the past decade, antiproliferative effects of somatostatin and analogs have been reported in many somatostatin receptor-positive normal and tumor cell types. Regarding the molecular mechanisms involved, somatostatin or analogs mediate their action through both indirect and direct effects. Somatostatin acts through five somatostatin receptors (SSTR1–5) which are variably expressed in normal and tumor cells. These receptors regulate a variety of signal transduction pathways including inhibition of adenylate cyclase, regulation of ion channels, regulation of serine/threonine and tyrosine kinases and phosphatases. This review focuses on recent advances in biological mechanisms involved in the antineoplastic activity of somatostatin and analogs.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lewin MJ: The somatostatin receptor in the GI tract. Annu Rev Physiol 1992;54:455–468.
  2. Epelbaum J, Dournaud P, Fodor M, Viollet C: The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8/1–2:25–44.
  3. Schally AV: Oncological applications of somatostatin analogues Cancer Res 1988;48:6977–6985.
  4. Weckbecker G, Raulf F, Stolz B, Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60/2:245–264.
  5. Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M: Scintigraphic imaging of pituitary adenomas: An in vivo evaluation of somatostatin receptors. J Endocrinol Invest 1998;21:512–519.
  6. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430–438.
  7. Reisine T, Bell GI: Molecular properties of somatostatin receptors. Neuroscience 1995;67:777–790.
  8. Meyerhof W: The elucidation of somatostatin receptor functions: A current view. Rev Physiol Biochem Pharmacol 1998;133:55–108.
  9. Kreienkamp HJ, Honck HH, Richter D: Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1). FEBS Lett 1997;419/1:92–94.
  10. Tallent M, Liapakis G, O’Carroll AM, Lolait SJ, Dichter M, Reisine T: Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 1996;71:1073–1081.

    External Resources

  11. Roosterman D, Glassmeier G, Baumeister H, Scherubl H, Meyerhof W: A somatostatin receptor 1 selective ligand inhibits Ca2+ currents in rat insulinoma 1046-38 cells. FEBS Lett 1998;425/1:137–140.
  12. Le Romancer M, Reyl-Desmars F, Cherifi Y, Pigeon C, Bottari S, Meyer O, Lewin MJ: The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity. J Biol Chem 1994;269:17464–17468.

    External Resources

  13. White RE, Schonbrunn A, Armstrong DL: Somatostatin stimulates Ca(2+)-activated K+ channels through protein dephosphorylation. Nature 1991;351:570–573.
  14. Renstrom E, Ding WG, Bokvist K, Rorsman P: Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin. Neuron 1996;17:513–522.

    External Resources

  15. Liebow C, Reilly C, Serrano M, Schally AV: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989;86:2003–2007.
  16. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91:2315–2319.
  17. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW: Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: Coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol 1997;11:1062–1069.

    External Resources

  18. Florio T, Rim C, Hershberger RE, Loda M, Stork PJ: The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol 1994;8:1289–1297.
  19. Murthy KS, Coy DH, Makhlouf GM: Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-β3 by Gβγ and inhibition of adenylyl cyclase by Gαi1 and Gα0. J Biol Chem 1996;271:23458–23463.
  20. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580–1584.

    External Resources

  21. Cordelier P, Esteve JP, Bousquet C, Delesque N, O’Carroll AM, Schally AV, Vaysse N, Susini C, Buscail L: Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype SSTR-5. Proc Natl Acad Sci USA 1997;94:9343–9348.
  22. Hou C, Gilbert RL, Barber DL: Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2. J Biol Chem 1994;269:10357–10362.
  23. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 1992;65:311–320.
  24. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WWS, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737–740.
  25. Serri O, Brazeau P, Kachra Z, Posner B: Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: Evidence for a direct and indirect mechanism of action. Endocrinology 1992;130:1816–1821.

    External Resources

  26. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL: Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.
  27. Canobbio L, Cannata D, Miglietta L, Boccardo F: Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: Clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 1995;15/6B:2687–2690.
  28. Ren SG, Ezzat S, Melmed S, Braunstein GD: Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 1992;131:2479–2481.
  29. Martinez V, Curi AP, Torkian B, Schaeffer JM, Wilkinson HA, Walsh JH, Tache Y: High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 1998;114:1125–1132.
  30. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J: Immunohistochemical localization of somatostatin receptor SSTR-2A in human pancreatic islets. J Clin Endocrinol Metab 1998;83:3746–3749.
  31. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997;15/1:77–86.
  32. Reubi JC, Horisberger U, Laissue J: High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction? Int J Cancer 1994;56:681–688.
  33. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW: Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest 1994;24/2:91–99.
  34. Tsutsumi A, Takano H, Ichikawa K, Kobayashi S, Koike T: Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells. Cell Immunol 1997;181:44–49.

    External Resources

  35. Casnici C, Lattuada D, Perego C, Franco P, Marelli O: Inhibitory effect of somatostatin on human T lymphocytes proliferation. Int J Immunopharmacol 1997;19:721–727.

    External Resources

  36. Elliott DE, Metwali A, Blum AM, Sandor M, Lynch R, Weinstock JV: T lymphocytes isolated from the hepatic granulomas of schistosome-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA. J Immunol 1994;153:1180–1186.
  37. Patel YC: Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348–367.
  38. Reubi JC, Schaer JC, Waser B, Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455–3459.
  39. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC: Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 1998;76:620–627.
  40. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C, Hollt V: Immunocytochemical detection of somatostatin receptors SSTR-1, SSTR-2A, SSTR-2B, and SSTR-3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047–2052.
  41. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K: Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375–2378.
  42. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C: Loss of SSTR-2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823–1827.

    External Resources

  43. Reubi JC, Waser B, Schaer JC, Markwalder R: Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995;80:2806–2814.
  44. Neel BG, Tonks NK: Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997;9/2:193–204.
  45. Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Esteve JP, Bedecs K, Buscail L, Vaysse N, Susini C: SSTR-2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase Shp-1. J Biol Chem 1998;273:7099–7106.
  46. Srikant CB, Shen SH: Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996;137:3461–3468.
  47. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Theveniau M, Nahmias C, Vaysse N, Susini C: The tyrosine phosphatase SHP-1 associates with the SSTR-2 somatostatin receptor and is an essential component of SSTR-2-mediated inhibitory growth signaling. J Biol Chem 1997;272:24448–24454.
  48. Florio T, Scorizello A, Fattore M, D’Alto V, Salzano S, Rossi G, et al: Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. J Biol Chem 1996;271:6129–6136.
  49. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688–1696.

    External Resources

  50. Sharma K, Srikant CB: G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification Biochem Biophys Res Commun 1998;242:134–140.
  51. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;27/1:11477–11483.
  52. Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;71:25–41.
  53. McWilliams DF, Watson SA, Crosbee DM, Michaeli D, Seth R: Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines. Gut 1998;42:795–798.
  54. Glassmeier G, Hopfner M, Riecken EO, Mann B, Buhr H, Neuhaus P, Meyerhof W, Scherubl H: Inhibition of L-type calcium channels by octreotide in isolated human neuroendocrine tumor cells of the gut. Biochem Biophys Res Commun 1998;250:511–515.

    External Resources

  55. Levy L, Bourdais J, Mouhieddine B, Benlot C, Villares S, Cohen P, Peillon F, Joubert D: Presence and characterization of the somatostatin precursor in ormal human pituitaries and in growth hormone secreting adenomas. J Clin Endocrinol Metab 1993;76/1:85–90.
  56. Reubi JC, Waser B, Lamberts SW, Mengod G: Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: Comparison with SRIH receptor content. J Clin Endocrinol Metab 1993;76:642–647.
  57. Nelson J, Cremin M, Murphy RF: Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. Br J Cancer 1989;59:739–742.

    External Resources

  58. Elliott DE, Blum AM, Li J, Metwali A, Weinstock JV: Preprosomatostatin messenger RNA is expressed by inflammatory cells and induced by inflammatory mediators and cytokines. J Immunol 1998;160:3997–4003.

    External Resources

  59. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C: SSTR-2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997;57:956–962.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50